Inverse Association Between BMI and Prefrontal Metabolic Activity in Healthy Adults

National Institute on Drug Abuse, Bethesda, Maryland, USA.
Obesity (Impact Factor: 4.39). 11/2008; 17(1):60-5. DOI: 10.1038/oby.2008.469
Source: PubMed

ABSTRACT Obesity has been associated with a higher risk for impaired cognitive function, which most likely reflects associated medical complications (i.e., cerebrovascular pathology). However, there is also evidence that in healthy individuals excess weight may adversely affect cognition (executive function, attention, and memory). Here, we measured regional brain glucose metabolism (using positron emission tomography (PET) and 2-deoxy-2[(18)F]fluoro-D-glucose (FDG)) to assess the relationship between BMI and brain metabolism (marker of brain function) in 21 healthy controls (BMI range 19-37 kg/m(2)) studied during baseline (no stimulation) and during cognitive stimulation (numerical calculations). Statistical parametric mapping (SPM) revealed a significant negative correlation between BMI and metabolic activity in prefrontal cortex (Brodmann areas 8, 9, 10, 11, 44) and cingulate gyrus (Brodmann area 32) but not in other regions. Moreover, baseline metabolism in these prefrontal regions was positively associated with performance on tests of memory (California Verbal Learning Test) and executive function (Stroop Interference and Symbol Digit Modality tests). In contrast, the regional brain changes during cognitive stimulation were not associated with BMI nor with neuropsychological performance. The observed association between higher BMI and lower baseline prefrontal metabolism may underlie the impaired performance reported in healthy obese individuals on some cognitive tests of executive function. On the other hand, the lack of an association between BMI and brain metabolic activation during cognitive stimulation indicates that BMI does not influence brain glucose utilization during cognitive performance. These results further highlight the urgency to institute public health interventions to prevent obesity.

  • Source
    • "The hypothesis regarding transfer of addiction seems more likely, following even longer periods post-bariatric surgery. While there is evidence for a decreased availability of D2R in obese subjects (Volkow et al., 2009), there is some controversy that argues this is only true for severe obesity (Eisenstein et al., 2013; Kessler, Zald, Ansari, Li & Cowan, 2014). Confounding variables include control cohorts from which other RDS behaviors have not been excluded, the use of BMI as a factor may not be appropriate as a phenotype and mild obesity may not indicate the real disorder. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Following the first association between the dopamine D2 receptor gene polymorphism and severe alcoholism, there has been an explosion of research reports in the psychiatric and behavioral addiction literature and neurogenetics. With this increased knowledge, the field has been rife with controversy. Moreover, with the advent of Whole Genome-Wide Studies (GWAS) and Whole Exome Sequencing (WES), along with Functional Genome Convergence, the multiple-candidate gene approach still has merit and is considered by many as the most prudent approach. However, it is the combination of these two approaches that will ultimately define real, genetic allelic relationships, in terms of both risk and etiology. Since 1996, our laboratory has coined the umbrella term Reward Deficiency Syndrome (RDS) to explain the common neurochemical and genetic mechanisms involved with both substance and non-substance, addictive behaviors.
    Journal of Behavioural Addictions 09/2014; 3(3):149-56. DOI:10.1556/JBA.3.2014.019
  • Source
    • "Obesity reduces regional cerebral blood flow, specifically to the prefrontal cortex, negatively impacting behaviors associated with that area thereby reducing executive functioning Pannacciulli et al., 2006; Walther et al., 2010; Willeumier et al., 2011. Reduced frontal lobe baseline metabolism correlates with body mass index (BMI), and negatively correlates with cognitive performance Mozley et al., 2001; Volkow et al., 2008. The extent of cognitive dysfunction seen in obese adults is highly variable Kanoski, 2012, perhaps caused by interactions or additive effects with related metabolic comorbidities. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite 50 years of pharmacological and psychosocial interventions, schizophrenia remains one of the leading causes of disability. Schizophrenia is also a life-shortening illness, caused mainly by poor physical health and its complications. The end result is a considerably reduced lifespan that is marred by reduced levels of independence, with few novel treatment options available. Disability is a multidimensional construct that results from different, and often interacting, factors associated with specific types and levels of impairment. In schizophrenia, the most poignant and well characterized determinants of disability are symptoms, cognitive and related skills deficits, but there is limited understanding of other relevant factors that contribute to disability. Here we conceptualize how reduced physical performance interacts with aging, neurobiological, treatment-emergent, and cognitive and skills deficits to exacerbate ADL disability and worsen physical health. We argue that clearly defined physical performance components represent underappreciated variables that, as in mentally healthy people, offer accessible targets for exercise interventions to improve ADLs in schizophrenia, alone or in combination with improvements in cognition and health. And, finally, due to the accelerated aging pattern inherent in this disease – lifespans are reduced by 25 years on average – we present a training model based on proven training interventions successfully used in older persons. This model is designed to target the physical and psychological declines associated with decreased independence, coupled with the cardiovascular risk factors and components of the metabolic syndrome seen in schizophrenia due to their excess prevalence of obesity and low fitness levels.
    06/2014; 1(2). DOI:10.1016/j.scog.2014.06.002
  • Source
    • "In addition to the striatum, the orbitofrontal cortex is also implicated in the motivation to feed (Rolls, 2004) and foodrelated stimuli activate the orbitofrontal cortex and trigger cravings in obese subjects (Wang et al., 2004). Interestingly, obese patients show lowered prefrontal metabolism which is inversely correlated with their individual body mass index and striatal D 2 receptor availability, suggesting that loss of dopaminergic orbitofrontal inhibitory control may contribute to the reinforcing properties of food associated with overeating in obese individuals (Volkow et al., 2009). In the present study, we found no evidence of altered forebrain baseline D 1 or D 2 receptor binding levels in the DIO rat. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tesofensine is a triple monoamine reuptake inhibitor which inhibits noradrenaline, 5-HT and dopamine reuptake. Tesofensine is currently in clinical development for the treatment of obesity, however, the pharmacological basis for its strong and sustained effects in obesity management is not clarified. Tesofensine effectively induces appetite suppression in the diet-induced obese (DIO) rat partially being ascribed to an indirect stimulation of central dopamine receptor function subsequent to blocked dopamine transporter activity. This is interesting, as obese patients have reduced central dopaminergic activity thought to provide a drive for compensatory overeating, but whether treatment with an uptake inhibitor counteracts these changes or not has not been investigated. Tesofensine treatment (2.0mg/kg/day for 14days) caused a pronounced anorexigenic and weight-reducing response in DIO rats as compared to age-matched chow-fed rats. DIO rats also exhibited a marked reduction in baseline extracellular dopamine levels in the nucleus accumbens (NAcc) and prefrontal cortex (PFC), as compared to chow-fed rats using microdialysis. While acute administration of tesofensine (2.0mg/kg) normalized accumbal dopamine levels in DIO rats, the drug had no effect on dopamine levels in chow-fed rats. Tesofensine evoked a stronger stimulatory response on NAcc and PFC dopamine levels in DIO rats, and also induced discrete changes in striatal dopamine D2 receptor expression and transporter binding. In conclusion, tesofensine produces weight loss together with reversal of lowered forebrain dopamine levels in DIO rats, suggesting that tesofensine's anti-obesity effects, at least in part, are associated with positive modulation of central dopaminergic activity.
    Pharmacology Biochemistry and Behavior 08/2013; 110. DOI:10.1016/j.pbb.2013.07.018 · 2.82 Impact Factor
Show more